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Background: Polycystic ovarian syndrome (PCOS) is characterized by increased ovarian angiogenesis and
vascularity. Accumulating evidence indicates that vascular endothelial growth factor (VEGF) is increased in PCOS
and may play an important role in these vascular changes and the pathogenesis of this disease. Placental growth
factor (PlGF), a VEGF family member, has not been previously characterized in PCOS women. We investigated levels
and temporal expression patterns of PlGF and its soluble receptor sFlt-1 (soluble Fms-like tyrosine kinase) in serum
and follicular fluid (FF) of women with PCOS during controlled ovarian stimulation.
Methods: This was a prospective cohort study of 14 PCOS women (Rotterdam criteria) and 14 matched controls
undergoing controlled ovarian stimulation. Serum was collected on day 3, day of hCG and day of oocyte retrieval. FF
was collected on retrieval day. PlGF, sFlt-1 and anti-mullerian hormone (AMH) protein concentrations were measured
using ELISA. Since sFlt-1 binds free PlGF, preventing its signal transduction, we calculated PlGF bioavailability as PlGF/
sFlt-1 ratio.
Results: Serum PlGF and sFlt-1 levels were constant throughout controlled ovarian stimulation, and no significant
differences were observed in either factor in PCOS women compared with non-PCOS controls at all three measured time
points. However, FF PlGF levels were increased 1.5-fold in PCOS women compared with controls (p < 0.01). Moreover,
FF PlGF correlated positively with number of oocytes retrieved and the ovarian reserve marker anti-mullerian hormone
(AMH) and negatively with age. In addition, FF sFlt-1 levels were decreased 1.4-fold in PCOS women compared to
controls (p = 0.04). PlGF bioavailability in FF was significantly greater (2-fold) in PCOS women compared with non-PCOS
controls (p < 0.01).
Conclusions: These data provide evidence that FF PlGF correlates with ovarian stimulation and that its bioavailability is
increased in women with PCOS undergoing controlled ovarian stimulation. This suggests that PlGF may play a role in
PCOS pathogenesis and its angiogenic dysregulation.
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Polycystic ovarian syndrome (PCOS) is a common endo-
crine disorder that affects 5-7% of women of reproductive
age [1]. Its cardinal features are hyperandrogenism, oligoa-
novulation and polycystic ovaries [1]. PCOS presents itself
with a wide spectrum of manifestations which may also* Correspondence: resheft@gmail.com
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unless otherwise stated.include obesity, hyperlipidemia, insulin resistance, type II
diabetes, and possibly cardiovascular disease [2,3].
The pathogenesis of PCOS is not well understood but
accumulating evidence suggests that dysregulation of
angiogenic factors may play an important role. Vascular
endothelial growth factor (VEGF) is the prototypical
member of a family of angiogenic factors which in-
cludes angiopoietins, placental growth factor (PlGF), basic
fibroblast growth factor (bFGF) and transforming growth
factor-β1 (TGF-β1). While we and others have shownThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ulated in PCOS, VEGF is the most extensively studied an-
giogenic factor in connection with PCOS pathophysiology
[8]. VEGF is one of the major regulators of angiogenesis
and its important role has been demonstrated in develop-
mental, physiological and pathological angiogenesis [9]. It
is a heparin-binding homodimeric protein of 46 kDa that
consists of six isoforms, and is a potent mitogen for endo-
thelial cells [9,10]. Its action is mediated by binding to
tyrosine kinase receptors, VEGFR-1 (Fms-like tyrosine
kinase: Flt-1) and VEGFR-2 (kinase domain-containing re-
ceptor: KDR/flk-1). Flt-1 is expressed in two forms via al-
ternative splicing at the pre-mRNA level; a full-length,
membrane-bound receptor, capable of transducing signal,
and a truncated, soluble receptor (sFlt-1), capable of se-
questering ligands or dimerizing with full-length receptors
and preventing signal transduction. It has been shown that
VEGF is overexpressed in the hyperthecotic ovarian stroma
of polycystic ovaries (PCO) [11,12]. In addition, several in-
vestigators reported VEGF to be increased in serum and
follicular fluid of PCOS women [5,13,14]. Moreover, sFlt-1,
the soluble receptor for VEGF, has been shown to be de-
creased in serum of PCOS women undergoing controlled
ovarian stimulation, contributing to increased VEGF bio-
availability [15]. Several studies have demonstrated in-
creased vascularity in the ovarian stroma of PCOS women
as measured by Doppler blood flow velocities [13,16,17].
This increased ovarian vascularity was shown to correlate
with increased serum VEGF levels in PCOS women
[13,18], further supporting the notion that VEGF contrib-
utes to the vascular changes observed in PCO.
PlGF displays 53% homology with VEGF and is a mem-
ber of the VEGF family which also includes VEGF-A,
VEGF-B, VEGF-C, VEGF-D and VEGF-E. It encodes four
isoforms (PlGF 1–4), composed of 131, 152, 203 and 224
amino acids after the removal of signal peptide (18 amino
acids residues in length), respectively [19]. While other
members of the VEGF family can bind both Flt-1 and Flk-1
receptors, PlGF binds exclusively Flt-1 receptor [20] with
high affinity compared to VEGF-A and VEGF-B, the other
members of the family able to specifically bind Flt-1 [21].
In cells co expressing VEGF and PlGF mRNA, a heterodi-
meric VEGF/PlGF protein has been described, in addition
to the VEGF and PlGF homodimeric forms. This VEGF/
PlGF heterodimer has been shown to promote capillary
growth in vivo [22].
The role of PlGF in PCOS pathophysiology has not been
previously investigated. We hypothesized that women
with PCOS may have elevated serum and/or follicular
fluid PlGF levels, which would be consistent with the in-
creased levels seen in its family member, VEGF. Accord-
ingly, the primary aim of our study was to investigate
PlGF and sFlt-1 dynamics in serum and follicular fluid of




We prospectively enrolled 14 PCOS women from women
undergoing controlled ovarian stimulation (COS) in prep-
aration for IVF or ICSI as previously described [6]. Diag-
nosis of PCOS was made according to the Rotterdam
consensus [23]. All 14 PCOS women had oligo- or amen-
orrhea and at least 12 follicles 2-9 mm in diameter per
ovary. Ten of the women had hyperandrogenemia and/or
hyperandrogenism, and four had normal serum androgen
levels and no clinical hyperandrogenism. Secondary causes
of androgen excess and anovulation were excluded. The
indications for COS in the PCOS group were male factor
(7 women), ovulatory dysfunction after failed superovula-
tion induction and intrauterine inseminations (4 women)
and tubal factor (3 women). Fourteen non-PCOS control
women undergoing COS in preparation for IVF or ICSI
were matched to PCOS women by age, BMI and use of
GnRH agonist/antagonist prior to enrollment. Inclusion
criteria for control non-PCOS women were normal ultra-
sonic ovarian morphology, normal ovulatory cycles and
no endocrine abnormalities. Inclusion criteria for all study
women were ages between 20–38, adequate visualization
of ovaries on transvaginal ultrasound and no hormonal
treatment i.e. OCPs. Exclusion criteria were diminished
ovarian reserve or endometriosis. The indications for
COS in the control group were male factor (9 women)
or tubal factor infertility (5 women). Patient clinical
characteristics are given in Table 1. This study was ap-
proved by Maimonides Medical Center institutional re-
view board. Written informed consent was obtained
from all participating women.
Women were treated using a stimulation protocol which
included either down regulation using a GnRH agonist in a
long protocol (n = 8 for each group) or a GnRH antagonist
to prevent premature ovulation (n = 6 for each group).
Ovarian stimulation was performed using a combination of
recombinant FSH and HMG. The standard stimulation
protocol was modified when there was risk of ovarian hy-
perstimulation or previous history of poor response. Fol-
licular monitoring by ultrasound and blood sampling for
estradiol levels were performed every 1–3 days. After the
first 3–5 treatment days, the daily dose could be adjusted
based on the follicular development and estradiol levels.
When at least six follicles with a diameter of 16 mm were
detected, either 5,000 or 10,000 IU hCG was administered,
depending on the estimated risk for hyperstimulation. Oo-
cytes were retrieved under transvaginal sonographic guided
needle puncture 35 hours following hCG administration.
Clinical pregnancy was defined as the presence of a gesta-
tional sac on ultrasound performed at 6 weeks after
Table 1 Patient clinical data
PCOS Non-PCOS P value
Age (years) 30.1 ± 4.4 30.8 ± 3.7 NS
Body mass index (Kg/m2) 25.5 ± 5.6 24.9 ± 3.9 NS
Serum AMH (ng/ml) 8.0 ± 6.5 3.1 ± 1.5 0.003
Day 3 FSH (mIU/ml) 5.2 ± 1.9 6.0 ± 2.7 NS
Total gonadotropin dose (IU) 2057 ± 868 2767 ± 1786 NS
Estrogen on day of hCG (pg/ml) 2819 ± 1158 2898 ± 860 NS
No. of aspirated oocytes 17.4 ± 10.5 12.6 ± 7.2 NS
Fertilization rate (%) 67.1 64.8 NS
Clinical pregnancy rate (%) 50.0 42.9 NS
Note: PCOS, polycystic ovarian syndrome; OHSS, ovarian hyperstimulation
syndrome; NS, not significant; values are given as mean “ standard deviation
or percentages. P-value <0.05 was considered statistically significant.
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number of fertilized oocytes divided by the number of oo-
cytes retrieved. The clinical pregnancy rate (CPR) was cal-
culated as the number of clinical pregnancies divided by
the number of embryo transfer procedures.Collection of blood and follicular fluid
Blood samples were obtained by venipuncture on cycle
day 3, day of hCG administration and day of oocyte re-
trieval. For AMH determination, blood samples were col-
lected within the period of 3 months prior to controlled
ovarian stimulation. After collection, the blood samples
were allowed to clot at room temperature for 30 min,
followed by centrifugation at 1200 rpm for 10 min. Serum
was stored in aliquots at −80°C until assayed. For follicular
fluid collection, follicles with a diameter of >16 mm were
aspirated. Only the first clear follicular fluid aspirate asso-
ciated with the presence of an oocyte, without blood or
flushing solution, was used for analysis. After removal of
the oocyte, the fluid was centrifuged at 1200 rpm for
10 min to remove granulosa cells and debris. The super-
natant was divided into aliquots and stored at −80°C until
assayed.PlGF, sFlt-1 and AMH ELISA assays
PlGF and sFlt-1 concentrations of serum and follicular
fluid samples were determined by ELISA according to the
manufacturer’s protocols (R&D, Minneapolis, MN), hav-
ing a sensitivity of 7.0 pg/mL and 3.5 pg/mL, respectively.
The intra- and inter-assay coefficients of variation for
PlGF and sFlt-1 ELISAs were 7.0% and 11.2%, and 3.2%
and 5.5%, respectively. AMH concentration of serum sam-
ples was determined according to the manufacturer’s pro-
tocols (Beckman and Coulter, Brea, CA). The assay
sensitivity was 0.16 ng/ml. The intra- and inter-assay coef-
ficients of variation were 4.3% and 7.4%, respectively. All
assays were performed in duplicate.Statistics
A power analysis powered for a two-tailed t-test was car-
ried out prior to subject enrollment to determine the mini-
mum required sample sizes needed to detect a 1.5-fold
(assumed) statistically significant difference in growth fac-
tor between cases (PCOS) and controls. The required level
of significance was at least 95% (p = 0.05), and the required
power of the test was at least 90% (p = 0.10). Based on this
calculation the required sample sizes were n = 14 for each
group. Data were analyzed by Student’s t-test or the
Mann–Whitney test, as appropriate. Results are expressed
as mean +/- standard error of the mean (SEM). Correla-
tions between PlGF or sFlt-1 and various parameters were
performed using Pearson correlation tests. SigmaStat (SPSS
Science, Chicago, IL) was used for statistical analysis. All
significance tests were two-tailed and P-value <0.05 was
considered to be statistically significant.
Results
Clinical characteristics and data of our study subjects
are shown in Table 1. As expected, PCOS women had a
significantly greater serum AMH level than the non-
PCOS control group (8.0 ± 6.5 ng/ml vs. 3.1 ± 1.5 ng/ml,
p = 0.003) (Table 1).
Follicular fluid PlGF protein concentration on day of oo-
cyte retrieval was increased approximately 1.5-fold in PCOS
women compared with non-PCOS controls (58.7 ± 19.5 vs.
38.6 ± 14.0 pg/ml, respectively, p = 0.006) (Figure 1A). No
differences were observed between PCOS and non-PCOS
women in serum levels of PlGF at all three measured time
points throughout controlled ovarian stimulation (Table 2).
Follicular fluid concentration of sFlt-1 was decreased 1.4-
fold in PCOS compared with non-PCOS women (2.7 ± 0.6
vs. 3.7 ± 0.5 ng/ml, respectively, p = 0.04) (Figure 1B). Simi-
larly, no differences were noted between PCOS and
non-PCOS women in sFlt-1 serum levels at all three
measured time points throughout controlled ovarian
stimulation (Table 3). Since sFlt-1 binds PlGF, reducing
its free levels and preventing its signal transduction, we
calculated PlGF bioavailability as a ratio of PlGF to sFlt-1
(PlGF/sFlt-1). PlGF bioavailability in follicular fluid was
significantly greater (2-fold) in PCOS women compared
with non-PCOS controls (0.022 vs. 0.01, respectively,
p < 0.01) (Figure 2).
Pearson correlation analysis was performed to evaluate
for correlations between PlGF or sFlt-1 concentration
and various stimulation cycle parameters. Follicular fluid
PlGF correlated positively with number of oocytes re-
trieved (r = 0.41, p = 0.03) and AMH (r = 0.60, p = 0.001),
and inversely with age (r = −0.38, p = 0.04) (Figure 3).
Follicular fluid PlGF was not found to correlate with
total gonadotropin dose administered (r = −0.29, p =
0.15), peak estrogen level (r = 0.16, p = 0.43) or day 3
FSH (r = 0.09, p = 0.66). With regards to stimulation
Figure 1 Follicular fluid PlGF and sFlt-1 concentrations. Follicular fluid concentration of PlGF (pg/ml) (A) and sFlt-1 (ng/ml) (B) in PCOS (polycystic
ovarian syndrome) and non-PCOS women undergoing controlled ovarian stimulation. Data are presented as mean ± standard deviation. *p < 0.05 for
PCOS vs. non-PCOS women.
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licular fluid PlGF and fertilization rate (r = −0.20, p =
0.34). Moreover, no difference was noted in follicular
fluid PlGF level between pregnant and non-pregnant
women (49.8 vs. 43.8 pg/ml, p = NS). No correlations
were found between follicular fluid sFlt-1 and either age,
AMH, day 3 FSH, total gonadotropin dose, peak estro-
gen level, number of oocytes retrieved, fertilization rate
or clinical pregnancy rate (data not shown).Discussion
This study is the first to report levels of PlGF in serum
and follicular fluid of women with PCOS undergoing con-
trolled ovarian stimulation. These data demonstrate that
follicular fluid PlGF concentration is increased while con-
centration of its soluble receptor sFlt-1 is decreased,
resulting in increased PlGF bioavailability in women with
PCOS. In addition, this study provides the first evidence
that follicular fluid PlGF is associated with serum AMH
and number of aspirated oocytes.
VEGF has been shown to be increased in ovarian tissue
[11,12] as well as serum and follicular fluid [5,13-15] of
PCOS women compared with non-PCOS controls. In
addition, sFlt-1, the soluble receptor for VEGF and PlGF,
has been reported to be decreased in serum and follicular
fluid of PCOS women undergoing controlled ovarianTable 2 Serum PlGF (pg/ml) in PCOS and non-PCOS
women during controlled ovarian stimulation
Group Day 3 hCG Oocyte retrieval
PCOS 9.6 ± 1.1 10.7 ± 1.4 10.1 ± 1.9
Control 9.7 ± 1.4 10.8 ± 2.0 10.1 ± 2.0
Note: PCOS, polycystic ovarian syndrome; values are mean “
standard deviation.stimulation, contributing to increased VEGF bioavailability
[15]. The increased serum VEGF levels in PCOS were
shown to correlate with increased ovarian vascularity in
these women [13,18], while laparoscopic ovarian drilling
has been shown to reduce Doppler indices of ovarian stro-
mal blood flow [24] with a concomitant reduction in circu-
lating VEGF levels [25], supporting the notion that VEGF
contributes to the vascular changes observed in PCO. Our
results demonstrate that follicular fluid PlGF, another im-
portant VEGF family member, is increased in PCOS and
suggest a role for PlGF overactivity in the pathogenesis of
PCOS. Additional research is warranted to investigate the
relative contribution of PlGF to the increased ovarian vas-
cularity and pathophysiology of PCOS. In contrast to VEGF,
which is increased in both serum and follicular fluid of
PCOS women [5,13-15], PlGF was not increased in serum
of PCOS women in our study. This difference may be due
to increased VEGF production in PCOS by non-ovarian
sources. In support of this, obesity and insulin resistance,
which are closely associated with PCOS, are characterized
by VEGF overproduction by adipose, vascular and bone-
marrow derived cells [26,27]. An alternative explanation for
the increased serum VEGF, but not serum PlGF, in PCOS
women may be increased ovarian production of VEGF rela-
tive to PlGF. However, the follicular fluid:serum ratio of
PlGF was found to be 4 to 6 fold in our study, which is
comparable to previously reported follicular fluid:serumTable 3 Serum sFlt-1 (ng/ml) in PCOS and non-PCOS
women during controlled ovarian stimulation
Group Day 3 hCG Oocyte retrieval
PCOS 55.9 ± 9.3 56.3 ± 7.9 57.2 ± 10.7
Control 58.1 ± 8.0 57.6 ± 7.4 55.2 ± 8.6
Note: PCOS, polycystic ovarian syndrome; values are mean “
standard deviation.
Figure 2 Follicular fluid PlGF bioavailability is increased in
PCOS. PlGF bioavailability (PlGF/sFlt-1 ratio) in follicular fluid (ng/ml) of
PCOS (polycystic ovarian syndrome) and non-PCOS women undergoing
controlled ovarian stimulation. Data are presented as mean ± standard
deviation. *p < 0.01 for PCOS vs. non-PCOS women.
Figure 3 Follicular fluid PlGF correlates with oocyte yield, AMH
and age. Correlations between follicular fluid levels of PlGF and (A)
number of oocytes retrieved, (B) AMH or (C) age in women with
polycystic ovarian syndrome or controls. Positive correlations were found
between PlGF and number of oocytes retrieved (r = 0.41, p = 0.03) and
between PlGF and AMH (r = 0.60, p = 0.001). PlGF and age correlated
inversely (r =−0.38, p = 0.04).
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likely.
AMH, or mullerian-inhibiting substance (MIS), is widely
considered a highly sensitive marker of ovarian reserve,
and has been shown to correlate with ovarian response to
stimulation during ART, as well as the risk of OHSS
[28,29]. In addition, AMH correlates inversely with age,
and its levels become undetectable in the serum of meno-
pausal women [30]. Our results revealed that follicular
fluid PlGF correlated positively with serum AMH and
number of oocytes retrieved while it correlated inversely
with age, suggesting that follicular fluid PlGF, similarly to
AMH, may be associated with ovarian response to stimu-
lation. While no studies, to the best of our knowledge,
have previously reported on associations between follicular
fluid PlGF and ART cycle stimulation/outcomes, previous
observations showed that follicular fluid VEGF correlates
positively with age and negatively with number of oocytes
retrieved and pregnancy rates [31,32]. These data suggest
that PlGF and VEGF, while belonging to the same VEGF
family, may have different biological roles in the local ovar-
ian microenvironment. Further studies are needed to con-
firm our data and investigate potential associations between
PlGF and ART outcomes.
Several lines of evidence indicate that PlGF is a potent
pro-angiogenic factor which contributes to pathological
angiogenesis. PlGF and VEGF have been demonstrated to
have similar potency in stimulating tissue factor produc-
tion and chemotaxis in monocytes [33]. In addition, PlGF
has been shown to stimulate angiogenesis and collateral
growth in ischemic heart and limb with efficiency at least
comparable to VEGF [34]. Moreover, Suzumori et al. have
reported that PlGF concentration is increased in peritoneal
fluid of women with endometriosis, and suggested that it
may contribute to the pathological neovascularizationcharacteristic of endometriotic lesions [35]. Since VEGF is
considered a key mediator of ovarian hyperstimulation syn-
drome (OHSS) by increasing vascular permeability, its
overexpression in PCOS has been suggested to contribute
to the increased risk of OHSS seen in these patients [36].
As the risk of OHSS is known to be greater in women re-
ceiving GnRH agonist protocol as compared to GnRH an-
tagonist protocol, we matched PCOS women to non-PCOS
women according to study protocol, eliminating this poten-
tial bias. In our study, follicular fluid PlGF was increased in
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retrieved i.e. ovarian stimulation. Thus, it is interesting to
speculate whether PlGF may play a similar role to VEGF in
OHSS. Indeed, transgenic mice overexpressing PlGF in
skin under the control of keratin-14 promoter showed a
substantial increase in number, branching and size of der-
mal blood vessels, together with enhanced vascular leaki-
ness [37], while inhibition of PlGF was associated with
reduced plasma extravasation in pathological conditions
[38]. Moreover, the gonadotropin LH, which is well-known
to stimulate VEGF leading to OHSS [39], has been shown
to increase the follicular fluid PlGF/sFlt-1 ratio in women
undergoing ovarian stimulation [40]. Further studies are
needed to evaluate the potential role of PlGF in OHSS
pathogenesis and examine its utility as a predictor for early
and/or late OHSS.
In the current study, PlGF concentration was 4 to 6-fold
greater in follicular fluid compared with serum, suggesting
that the ovary is the primary site of production of follicular
fluid PlGF. Consistent with our data, Gutman et al. re-
ported higher levels of PlGF in follicular fluid compared
with plasma (where levels were undetectable) in women
undergoing IVF [40]. A possible explanation for the differ-
ences in ability to measure PlGF in the circulation between
the studies is the different type of sample medium used
(i.e. serum vs. plasma). Follicular fluid is the product of
diffusion of blood constituents across the blood-follicle
barrier and of molecules secreted by granulosa and theca
cells. Although it is unknown which ovarian compart-
ment may be responsible for PlGF production, there is a
strong body of evidence that ovarian granulosa and endo-
thelial cells are the main source of production of VEGF
during hyperstimulation [36,41], and it s reasonable to
hypothesize that PlGF is produced by similar mecha-
nisms. In-vitro and animal experiments are needed to
clarify this point further.
Conclusions
This is the first study to characterize serum and/or fol-
licular fluid levels of PlGF in PCOS during controlled
ovarian stimulation. Our study provides evidence that
follicular fluid PlGF correlates with ovarian stimulation
and that its bioavailability, as measured by the PlGF/sFlt-1
ratio, is increased in women with PCOS. Results of this
study suggest that PlGF may play a role in the angiogenic
dysregulation characteristic of PCOS and its predispos-
ition to OHSS. Further studies are warranted to investi-
gate these possibilities.
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